Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Total Liabilities (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Total Liabilities for 5 consecutive years, with $7.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities fell 56.79% to $7.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.0 million, a 56.79% decrease, with the full-year FY2024 number at $15.4 million, down 3.39% from a year prior.
  • Total Liabilities was $7.0 million for Q3 2025 at Mereo BioPharma, down from $8.5 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $26.0 million in Q4 2022 to a low of -$54.7 million in Q3 2023.
  • A 4-year average of -$1.7 million and a median of $10.8 million in 2024 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: surged 135.19% in 2024, then plummeted 56.79% in 2025.
  • Mereo BioPharma's Total Liabilities stood at $26.0 million in 2022, then crashed by 38.63% to $16.0 million in 2023, then decreased by 3.39% to $15.4 million in 2024, then tumbled by 54.58% to $7.0 million in 2025.
  • Per Business Quant, the three most recent readings for MREO's Total Liabilities are $7.0 million (Q3 2025), $8.5 million (Q2 2025), and $8.2 million (Q1 2025).